Purpose

Cancer-inflammation prognostic index (CIPI) is calculated by multiplying the concentration of carcinoembryonic antigen by neutrophil-to-lymphocyte ratio. CIPI has been reported as a prognostic factor for colorectal cancer. Although carcinoembryonic antigen and neutrophil-to-lymphocyte ratio have been reported as prognostic factors for non-small cell lung cancer (NSCLC), it has not been investigated whether CIPI is a useful marker.

Methods

We analyzed the prognostic factors, including CIPI, in 700 NSCLC patients treated by pulmonary resection. We also analyzed a subgroup of 482 patients with pathological stage I NSCLC.

Result

CIPI > 14.59 (P < 0.01), maximum standardized uptake value (SUV_max) > 5.35 (P < 0.01), lymphatic invasion (P = 0.01), and pathological stage (P < 0.01) were significant factors for relapse-free survival (RFS) in multivariate analysis. SUV_max > 5.35 (P < 0.01) and pathological stage (P < 0.01) were revealed as significant factors for overall survival in the multivariate analysis. In the subanalysis, CIPI > 14.88 (P = 0.01) and SUV_max > 5.07 (P < 0.01) were significant factors for RFS of pathological stage I NSCLC in multivariate analysis.

Conclusion

CIPI was a significant factor for RFS in NSCLC patients treated surgically, even in those with pathological stage I disease. SUV_max was also a significant factor for RFS and overall survival in NSCLC patients treated surgically, and for RFS in patients with pathological stage I NSCLC.

Trial Registration

The Institutional Review Board of Kanazawa Medical University approved the protocol of this retrospective study (Approval Number: I392), and written informed consent was obtained from all patients.

中文翻译：

---

癌症炎症预后指数对非小细胞肺癌的预后影响

目的

癌症炎症预后指数（CIPI）是通过将癌胚抗原的浓度乘以中性粒细胞与淋巴细胞的比率来计算的。据报道，CIPI 是结直肠癌的预后因素。尽管癌胚抗原和中性粒细胞与淋巴细胞比率已被报道为非小细胞肺癌 (NSCLC) 的预后因素，但尚未研究 CIPI 是否是有用的标志物。

方法

我们分析了 700 名接受肺切除术治疗的 NSCLC 患者的预后因素，包括 CIPI。我们还分析了 482 名病理学 I 期 NSCLC 患者的亚组。

结果

CIPI > 14.59（P  < 0.01）、最大标准化摄取值（SUV _max）> 5.35（P  < 0.01）、淋巴管侵犯（P  = 0.01）和病理分期（P  < 0.01）是无复发生存的显着因素（ RFS）在多变量分析中。 在多变量分析中，SUV _max  > 5.35 ( P  < 0.01) 和病理分期 ( P < 0.01) 被认为是总体生存的重要因素。亚组分析中，CIPI>14.88（P  =0.01）和SUV _max  >5.07（P  <0.01）是多因素分析中影响病理I期NSCLC RFS的显着因素。

结论

CIPI 是手术治疗 NSCLC 患者 RFS 的一个重要因素，即使是那些患有病理学 I 期疾病的患者。SUV _max也是手术治疗 NSCLC 患者 RFS 和总生存率以及病理 I 期 NSCLC 患者 RFS 的重要因素。

试用注册

金泽医科大学机构审查委员会批准了本次回顾性研究的方案（批准号：I392），并获得了所有患者的书面知情同意书。